A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Files

Name: A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Files
Creator: Brett King
Published: 2021-03-16T10:23:07.655Z
Keywords: Alopecia Areata, Janus Kinase

King, Brett

doi:10.17632/f5jkpm4mxh.1

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Files

Published: 16 March 2021| Version 1 | DOI: 10.17632/f5jkpm4mxh.1

Contributor:

Brett King

Description

Supplementary Figures 1-6. Supplementary Tables 1-5

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results. Supplementary Files

Description

Files

Categories

Licence